載入...
Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
During the last several years, multiple gene rearrangements with oncogenic potential have been described in NSCLC, identifying specific clinic-pathological subgroups of patients that benefit from a targeted therapeutic approach, including anaplastic lymphoma kinase (ALK), c-ros protooncogene 1 (ROS1...
Na minha lista:
| 發表在: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
AME Publishing Company
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7815353/ https://ncbi.nlm.nih.gov/pubmed/33489820 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-2019-cnsclc-06 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|